



Dermatology Reports

<https://www.pagepress.org/journals/index.php/dr/index>

eISSN 2036-7406



Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. **Dermatology Reports** is, therefore, E-publishing PDF files of an early version of manuscripts that undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one. The final version of the manuscript will then appear on a regular issue of the journal. E-publishing of this PDF file has been approved by the authors.

Please cite this article as: Fabio Massimo Gavazzoni, Federico Patta, Carla Nobile, Ilaria Girolami. Lichen Planus Pigmentosus Inversus: case report and systematic review. Dermatol Rep 2024 [Epub Ahead of Print] doi: 10.4081/dr.2024.10000

© the Author(s), 2024
Licensee [PAGEPress](https://www.pagepress.org/), Italy

Submitted 24/03/24 – Accepted 31/08/24

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Lichen Planus Pigmentosus Inversus: case report and systematic review

Fabio Massimo Gavazzoni,¹ Federico Patta,¹ Carla Nobile,¹ Iliaria Girolami²

¹Department of Dermatology, Hospital of Brunico (SABES-ASDAA), Brunico;

²Department of Pathology, Provincial Hospital of Bolzano (SABES-ASDAA), Bolzano, Italy;

Corresponding author: Iliaria Girolami, Department of Pathology, Provincial Hospital of Bolzano (SABES-ASDAA), L. Böhler Straße, 5, 39110, Bolzano-Bozen, Italy.

Tel. +39 0471 438153.

E-mail: Iliaria.girolami@sabes.it

Key words: Lichen Planus Pigmentosus Inversus, case report, systematic review.

Authors' contributions: FMG, FP data analysis and curation, review and approval of manuscript; CN review and approval of manuscript; IG draft writing, data analysis and curation. All the authors have read and approved the final version of the manuscript and agreed to be held accountable for all aspects of the work.

Conflict of interest: the authors declare no potential conflict of interest.

Funding: none.

Ethics approval and consent to participate: institutional ethical approval is waived for case reports.

Informed consent: the patient consented to the publication.

Availability of data and materials: data sharing does not apply to this article as no datasets were generated or analyzed during the current study.

Abstract

Lichen Planus Pigmentosus Inversus (LPPI) is a rare variant of lichen planus characterized by well-demarcated, often slight pruritic, dark-gray plaques in intertriginous zones, hence the attribute of “inversus”, originally described by Pock *et al.* in 2001. Less than 100 cases have been reported to date, and here we present a case in a 52-year-old male who presented with two months duration of grey-brownish plaques in bilateral axillary, submammary, antecubital, and inguinal folds. No triggering agent was present, and the biopsy showed an interface/lichenoid dermatitis with plenty of pigment incontinence. Topical tacrolimus 0.1% ointment was administered with moderate improvement at five weeks. A review of the literature showed no significant differences in involved sites and age distribution among genders, with a slightly longer duration of manifestations in females. The most administered therapeutic agents were topical corticosteroids, alone or in combination with other agents, and tacrolimus.

Introduction

Lichen Planus Pigmentosus Inversus (LPPI) is a rare variant of lichen planus characterized by well-demarcated, often slight pruritic, dark-gray plaques in intertriginous zones such as the axilla and inguinal areas, hence the attribute of “inversus”. Originally described by Pock *et al.* in 2001,¹ less than 100 cases have been reported to date. Etiology is not yet elucidated, with some reporting association with hepatitis C² and triggering by chemicals, metals, or friction by tight-fitting clothes.³⁻⁵ Standard therapy is not established, with reported variable clinical improvement with steroids and tacrolimus, but with a general impression of a more resistant disease than common lichen planus. Here we present a case of LPPI in a light-skinned Caucasian male with no other dermatologic conditions nor comorbidities together with a systematic review of the reported cases with a focus on gender differences and response to therapy.

Case Report

A 52-year-old fair-skinned Caucasian man presented with well-demarcated, oval grey-brownish slightly pruritic plaques in the axillary, submammary, antecubital, and inguinal folds bilaterally of two months duration (Figure 1). The patient had no significant comorbidities and denied a recent history of trauma, infection, drug use intake, or use of new oils, perfumes, or antiperspirants. Previous treatment with topical corticosteroids and antifungal agents was ineffective. Microbiological testing for fungi and skin bacteria was negative. A punch biopsy was performed and histological examination showed a superficial, band-like inflammatory infiltrate composed of small lymphocytes with exocytosis in the epidermis, together with features of lichenoid inflammation and interface damage such as hypergranulosis, mild hyperkeratosis, sparse individual necrotic basal keratinocytes and diffuse evident deposition of pigment with numerous melanophages (Figure 2). A melanocytic component was excluded with a MelanA immunohistochemical stain as well as fungal infection with periodic acid-Schiff staining. Taking together the histological features and the clinical appearance, a diagnosis of LPPI was established. The patient was treated with tacrolimus ointment 0.1% twice a

day for 5 weeks with moderate improvement of the lesions. Subsequently therapy was switched to isotretinoin to improve renewal of skin layers and has been ongoing for two months at the time of publication with moderate improvement.

We inspected published literature in Pubmed and grey literature to gather evidence on potential peculiar epidemiological and clinical features and experience on the effectiveness of therapy. Articles reporting on single cases or case series were reviewed and information on demographics, sites of involvement, symptoms and their duration, comorbidities, therapy, and follow-up were extracted and tabulated in an Excel spreadsheet. When available, differences in distribution among males and females were tested with a parametric test for continuous variables and a Chi-squared test for categorical variables, with significance at $p=0.05$, with the use of free online calculators.

Results of the search

We inspected published literature in Pubmed and grey literature to gather evidence on potential peculiar epidemiological and clinical features and experience on the effectiveness of therapy. By searching Pubmed for “lichen planus pigmentosus inversus” a total of 41 records were retrieved ranging from the first description in 2001 to very recent cases in 2023 (Supplementary Table S1). With additional reference searching a total of 49 publications of single cases or case series were retrieved, with a total of 98 patients with an age range of 5-84 years (mean 54.8 ± 18.3 , median 58, Interquartile Range, IQR 45-68) and 62 (63.3%) females and 36 (36.7%) males. Age distribution did not differ between males and females (male mean age 56.4 ± 17.5 , median 58.5 vs female mean age 53.9 ± 18.7 , median 54.5, $p=0.52$). Slight pruritus was present in 44 (44.9%) patients, 43 (43.9%) were asymptomatic, and in 11 (11.2%) instances this was not reported, with no significant difference between males and females (56.7% vs 47.4% , $p=0.50$). Caucasian patients were 29 (29.6%), followed by Asiatic and Middle Eastern patients together were 25 (25.5%), then 13 (13.3%) were of African descent and 5 (5.1%) categorized as Hispanic; however, in 26 (26.5%) cases, ethnic background was not stated clearly. Axillar involvement was present in 70 (71.4%) of cases, alone or with other sites

involvement, followed by groins/inguinal folds in 55 (56.1%) cases, submammary folds with 29 (29.6%) cases, neck folds in 13 (13.3%) cases and popliteal folds with 11 (11.2%) cases; in 7 (7.1%) instances the site was not reported. As reported in a recent case, unilateral involvement is uncommon.⁶ Regarding the duration of lesions, the median duration of symptoms was 6 months (IQR 9.75-12) in a range of 0.3-180 months, with a longer median duration in females than in males (median 6 vs 3 months, $p=0.03$).

Indeed, in the published cases follow-up after the start of therapy ranged 0.75-12 months with a median of 3 months (IQR 2-6), with no differences among males and females (median 4 vs 3 months, $p=0.20$). The most used therapeutic agents were topical corticosteroids alone in 35 cases (35.7%) or in combination with other agents in 9 cases (9.2%), followed by topical tacrolimus alone or with other agents in 15 cases (15.3%). Other agents used were oral corticosteroids (3, 3.1%), Chinese herbs (3, 3.1%), narrow-band UVB (2, 2%), and a propolis creme (1, 1%). In 21 (21.4%) cases, however, information regarding therapy was not reported, while in 4 (4.1%) cases no therapy was administered and no information on follow-up was present. In 12 of 44 cases with the use of corticosteroids alone or in combination with other agents, there was a relevant response with corticosteroids, while in 32 of 44, there was little or no response; therapy based on tacrolimus alone or in combination resulted in an improvement of lesions in 6 of 15 cases. However, therapeutic regimens were too different in terms of specific agent, dose, and length of administration to allow a conclusion on the comparison of effectiveness.

Discussion

LPPI is a rare variant of Lichen Planus Pigmentosus (LPP) with less than 100 cases reported to date. Differently from LPP which is more frequently reported in dark-skinned patients with phototype III-VI coming from India, Asia, and Latin America, LPPI was first described in Europe and it is diffused worldwide.⁵ Etiology is not yet elucidated, with some association reported with hepatitis C² and triggering by chemicals, metals, or friction by tight-fitting clothes.³⁻⁵ Our patient had no remarkable

medical history nor suspected risk factors. Moreover, no special triggers were found, particularly infectious conditions or the recently described association with Covid-19 vaccination.⁷⁻⁹ Diagnosis is usually suspected clinically, but there are reports of the utility of dermatoscopy and line-field confocal optical coherence tomography.^{6,10} Our patient showed characteristics similar to what was found in the literature and also the therapy administered was in line with what was found in literature, as tacrolimus was the second most commonly administered agent, and showed a slight improvement of disease, again in line with what was found in the literature.

In conclusion, LPPI is an uncommon disease with yet unelucidated etiology, with literature suggesting a broad spectrum of presentation in terms of age and ethnicity, a longer duration of disease in females and variable response to common therapies such as corticosteroids and tacrolimus. Given the rarity of the disease, a high level of suspicion is necessary, and only histological examination can lead to confirmation of the diagnosis after clinic-pathological correlation.

References

1. Pock L, Jelínková L, Drlík L, et al. Lichen planus pigmentosus-inversus. *J Eur Acad Dermatol Venereol.* 2001;15:452-4.
2. Bennàssar A, Mas A, Julià M, et al. Annular plaques in the skin folds: 4 cases of lichen planus pigmentosus-inversus. *Actas Dermosifiliogr.* 2009;100:602-5.
3. Ohshima N, Shirai A, Saito I, Asahina A. Lichen planus pigmentosus-inversus occurring extensively in multiple intertriginous areas. *The Journal of Dermatology.* 2012;39:412-4.
4. Barros HR, Almeida JRP de, Mattos e Dinato SL, et al. Lichen planus pigmentosus inversus. *An Bras Dermatol.* 2013;88:146-9.
5. Robles-Méndez JC, Rizo-Frías P, Herz-Ruelas ME, et al. Lichen planus pigmentosus and its variants: review and update. *Int J Dermatol.* 2018;57:505-14.
6. Lamberti A, Falcinelli F, Cinotti E, et al. Unilateral lichen planus pigmentosus inversus: Line-field confocal optical coherence tomography features and histopathological correlation. *J Eur Acad Dermatology Venereol.* 2024;38:e799-801.
7. Edek YC, Tamer F, Öğüt B. Lichen planus pigmentosus inversus with nail involvement following COVID-19 vaccination: A case report. *Dermatologic Therapy.* 2022;35:e15809.
8. Sun L, Duarte S, Soares-de-Almeida L. Case of lichen planus pigmentosus-inversus after Oxford-AstraZeneca COVID-19 vaccine: cause or coincidence? *Journal of the European Academy of Dermatology and Venereology : JEADV.* 2022;36:e514-6.
9. Gil-Quiñones SR, Velandia JA, Velandia F, Barrera MY. Lichen planus and lichen planus pigmentosus inversus following COVID-19 vaccine in dark phototype patients. *Actas dermo-sifiliograficas.* Spain; 2024;115:609-11.
10. Roster K, Tarawneh OH, Zufall A, et al. Dermatoscopic rainbow pattern in lichen planus pigmentosus inversus in a middle-aged African American man. *JAAD Case Reports.* 2023;35:118-21.




Figure 1. Distribution of lesions on submammary folds (a), abdomen (b) and axilla (c).




Figure 2. Biopsy showing a lichenoid dermatitis with band-like chronic infiltrate, interface changes such as vacuolization and cytoid bodies, and diffuse deposition of brown pigment in the superficial dermis. Hematoxylin and eosin, 20x magnification (a, b).

Online supplementary materials.

Supplementary Table 1. By searching Pubmed for “lichen planus pigmentosus inversus” a total of 41 records were retrieved ranging from the first description in 2001 to very recent cases in 2023.